Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.

EyeWorld Weekly, March 15, 2024

➤ Phase 3 clinical trial for water-free dry eye cyclosporine drop ➤ Phase 2b results for drug-eluting contact lens for glaucoma ➤ Dosing continues for Phase 1/2 trial evaluating gene therapy for X-linked retinoschisis ➤ Higher dose, extended wet AMD treatment non-inferior to standard of care ➤ Study: AI detects severe retinopathy of prematurity with 100% accuracy ➤ Complimentary access to video journal ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, March 15, 2024

EyeWorld Weekly, March 8, 2024

➤ FDA approves new drug for postop inflammation and pain ➤ Primary endpoints in unadjusted population not met in Phase 3 trial for dry eye drop ➤ Study links inherited eye diseases to gut bacteria ➤ Acquisitions and other news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, March 8, 2024

EyeWorld Weekly, March 1, 2024

➤ Enrollment complete in Phase 2 study for drug targeting endocannabinoid system for IOP lowering ➤ Dosing complete for Phase 1/2 trial evaluating a gene therapy for Stargardt disease ➤ Pre-Phase 3 Type B meeting held with FDA by company focused on retinitis pigmentosa ➤ Updates from several late-stage clinical trials ➤ New company launches to pioneer nonviral gene therapies ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, March 1, 2024

EyeWorld Weekly, February 23, 2024

➤ Study: artificial intelligence matches/outperforms ophthalmologists ➤ Primary endpoint met in Phase 3 trial using an antibody to treat thyroid eye disease ➤ FDA grants Breakthrough Device Designation to novel spectacle design ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 23, 2024

EyeWorld Weekly, February 16, 2024

➤ FDA approves IND for neuropathic pain drug ➤ Phase 2 preliminary efficacy and safety data for wet AMD treatment trial ➤ First-in-human data for DME, AMD therapy ➤ Study: Rapid eye stroke detection protocol helps prevent vision loss ➤ Enrollment complete for Phase 3 trial for sozinibercept ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 16, 2024

EyeWorld Weekly, February 9, 2024

➤ FDA warns against copycat eye drops ➤ Generic drop receives FDA approval ➤ Topline data revealed in two presentations ➤ New 72-week data from Phase 3 RVO treatment studies ➤ First patient dosed in Phase 2/3 trial for GA treatment ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 9, 2024

EyeWorld Weekly, February 2, 2024

➤ FDA approves first IND for RNA exon editor ➤ SPA granted for Phase 3 trial of an intravitreal implant for wet AMD ➤ Study: retinal imaging helps predict risk of developing a host of diseases ➤ European Medicines Agency recommends rejection of pegcetacoplan for GA ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 2, 2024

EyeWorld Weekly, January 26, 2024

➤ FDA agrees to special protocol assessment for AMD clinical trial ➤ Topline data from Phase 2 trial evaluating suprachoroidal wet AMD treatment ➤ First patient dosed in Phase 1 DME treatment study ➤ Study: new gene variants contributing to glaucoma susceptibility identified ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, January 26, 2024

EyeWorld Weekly, January 19, 2024

➤ FDA approves updated femtosecond laser for refractive surgery ➤ Positive topline results from Phase 3, first-in-class dry eye disease studies ➤ Rare Disease Designation granted for investigational gene therapy ➤ Positive interim data for investigational Stargardt disease treatment ➤ First patient dosed in Phase 2 trial for DME treatment ➤ Research program established to investigate whole eye transplant ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, January 19, 2024

EyeWorld Weekly, January 12, 2024

➤ FDA approves new excimer laser technology ➤ Phase 3 trial to evaluate phentolamine for treatment of decreased visual acuity ➤ Phase 2 trial of investigational dry eye drug sees effect on signs and symptoms ➤ Study has new findings to promote corneal healing ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, January 12, 2024